Fast Melt Tablets Market

Fast Melt Tablets Market Forecast and CAGR:

According to the latest research by Fact.MR, the fast melt tablets market is set to observer a growth of 9-10% during the forecast period. Demand for fast melt tablets expects to observer stable recovery in the short-term, with a positive growth position in the long run. High adoption of fast melt tablets technology will offer lucrative opportunities in near future.

What are the major drivers of the Fast Melt Tablets Market?

Fast melts tablet is an oral solid dosage form which disintegrates in the oral cavity without water or chewing. Fast or mouth dissolving tablets have been formulated for active patients who are busy in travelling, may not have access to water, patient who can’t swallow. It is highly adopted by pediatric, geriatric, and bedridden patients.

Because of various innovations in the field of oral-dissolving drug delivery system, they can now be used for numerous benefits such as rapid drug therapy intervention, increased bioavailability, good stability, easy manufacturing, unite and accurate dosing, easy handling, motion sickness, suede episodes of allergic attack or coughing, where an ultra-rapid onset of action required.

The increase in the elderly population, who cannot swallow medicine, the increase in product promotion aimed at raising awareness of the treatment of patients. Rise in demand for patient compliance and cost-effective products to improve the quality of patients’ lives.

Due to administration of oral solid traditional formulations there is a risk of chocking or suffocation. In addition, technological innovations in fast melt tablet who meet pharmacopeia requirement where tablet disperses rapidly before swallowing and which disintegrates in less than 3 minutes. This have further supplemented the market growth.

High Adoption of Fast Melt Tablets Expected To Boost the Demand.

High adoption of fast-melt tablet by geriatric population give demand progress for fast melt tablets market during the forecast period. First pass metabolism is big issue in a conventional oral formulation that can be prevented with the help of fast melt tablet.

These drug delivery systems are capable of achieving patient compliance a great extent which boosts the demand. Self-administration is possible with high bioavailability and immediate action and decreased side effect of drug to patients. This are the formulation driving force for more adoption.

However, some technological challenges that may create hindrance in this drug delivery system can be the overcome with extensive research in formulation and development. This add on to more adoption of this fast-melt tablet.

North America Fast Melt Tablets Demand Outlook

Due to the market player innovation, the North American market occupies an important part of the global demand.  The major factors that makes the North American market largest revenue generating region in this field are the presence of major companies manufacturing the advance drug delivery system who are funding various R&D activities for the market. Along with the above mentioned factors, the increased disposable income and various developments in the healthcare industry are other key factors leading to market dominance.

Europe Fast Melt Tablets Demand Outlook

Europe being the second most dominating region in this field, due to high percentage of geriatric population. According to the research done by Eurostat in 2019, there were 90.4 Mn older people. Geriatric population is the adopting due to swallowing issues and gastrointestinal track is also week of old age patient so that adopt more fast melt tablet. Also, a rising incidence of heart attack in Europe so in such cases fast melt tablets act for rapid delivery and immediate action. This are some factors that can drive the market.

Who are the key players in the Fast Melt Tablets Market?

Some of the manufacturers of fast melt tablet are

• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• AstraZeneca
• Mylan N.V.
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• F. Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Bausch Health
• GlaxoSmithKline plc
• Sun Pharmaceutical Industries Ltd.
• Bayer AG
• Eli Lily and Company
• Dr. Reddy’s Laboratories Ltd.
• Takeda Pharmaceutical Company Limited
• Kissei Pharmaceutical Co.Ltd.

For instance in June 2019, Kissei Pharmaceutical Co., Ltd. launched GLUBES® which is the new orally disintegrating dosage form of GLUBES® Combination Tab.

Fast Melt Tablets Market Report Highlights:

• Shifting Industry dynamics
• In-depth market segmentation
• Historical, current and projected industry size recent industry trends
• Key Competition landscape
• Strategies for key players and product offerings
• Potential and niche segments/regions exhibiting promising growth
• A neutral perspective towards market performance

Key Segments:

• By Drug Class:

  • Anti-Psychotics
  • Anti-Epileptics
  • CNS Stimulants
  • Anxiolytics
  • Anti-Parkinsonian Drugs
  • Anti-Hypertensive
  • NSAIDS
  • Anti-Allergy Drugs
  • Proton Pump Inhibitors
  • Others

• By Indication

  • CNS Diseases
  • GI Diseases
  • CVS Disorders
  • Allergy
  • Others

• By Distribution channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

• By region:

  • North America:
  • Latin America
  • Europe:
  • East Asia:
  • South Asia:
  • Oceania:
  • Middle East and Africa:

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

NOTE: Although care has been taken to maintain the highest levels of accuracy in reports, recent market/vendor-specific changes may time to reflect in the analysis.